Quiver Bioscience’s cover photo
Quiver Bioscience

Quiver Bioscience

Biotechnology Research

Cambridge, MA 6,403 followers

Decoding Brain Disease to Reimagine Drug Development

About us

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

Website
http://www.quiverbioscience.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Cambridge, MA
Type
Privately Held
Founded
2013
Specialties
Precision Medicine, Machine Learning, Genomics, Neurology, Drug Discovery, Personalized Medicine, Genetic Therapies, Optical Electrophysiology, Gene Editing, Stem Cells, Optogenetics, Transcriptomics, Human Models, Therapeutic Design & Screening, Cardiology, Rare Disease, Neurodegenerative, Disrupting Medicine, and Functional Genomics

Locations

Employees at Quiver Bioscience

Updates

  • The brain speaks with a unique language - electrical signals firing across billions of neurons, driving thought, movement, emotion, and memory. When that language breaks down, the consequences are profound: epilepsy, ALS, rare neurodevelopmental disorders, and countless conditions that have long resisted conventional drug discovery. At Quiver Bioscience, we've built a platform designed to listen and translate. The result is a fundamentally different foundation for CNS drug discovery grounded in neuronal function. The Quiver team celebrates Brain Awareness Week 2026 🧠 #BrainAwarenessWeek #Neuroscience #CNS #DrugDiscovery

    • No alternative text description for this image
  • Congratulations to this year’s Brain Prize winners – David Ginty and Patrik Ernfors.   Their foundational work in sensory neuron biology has transformed our understanding of how pain signals are generated and maintained in the nervous system. These foundational insights are now enabling the next generation of pain therapeutics including Quiver’s own novel non-opioid treatment for chronic pain.

    Huge congratulations to the Brain Prize winners of 2026! This year's Brain Prize is awarded to Professors David Ginty (Harvard Medical School, US) and Patrik Ernfors (Karolinska Institutet, Sweden) for their pioneering discoveries on how the nervous system detects and processes touch and pain. Together, their work has transformed our understanding of how stimuli are detected and transduced into neural signals, and how these signals are processed and integrated as they travel to the brain to allow perception of our physical interactions with the world. For decades, scientists lacked a clear understanding of how many distinct sensory neuron types exist, how they are constructed, and how their signals are organized and routed to the central nervous system. The Brain Prize winners have radically changed the field. By identifying and classifying distinct sensory neuron types, linking them to specific end organs and neural pathways, and developing widely used genetic and molecular tools, they have established a blueprint for understanding touch and pain—and for pinpointing what goes wrong in conditions such as chronic pain and hypersensitivity. Their work has rewritten textbook principles of somatosensation and provided the foundation for a new generation of targeted interventions for pain and disorders of touch based on specific cell types and neural pathways. Learn more about the two prize winners and their discoveries: https://lnkd.in/eQk9TayB Howard Hughes Medical Institute (HHMI)

    • No alternative text description for this image
  • Rare Disease Day is a powerful reminder of why we at Quiver Bioscience dedicate ourselves to this work every day. Thank you to Charlene Son Rigby (STXBP1 Foundation), Emily Barnes (Cure SYNGAP1), and Isabel Aznarez (Stoke Therapeutics) for joining us at Quiver last week to share unique perspectives on rare neurological disorders! From individual lived experiences with STXBP1 and SYNGAP1-related disorders to the inspiring story of ASO therapeutic development for Dravet syndrome, the conversation underscored the power of collaboration between patients, advocates, and researchers. Progress in rare diseases depends on listening, partnership, and persistence. We’re proud to stand alongside this community in advancing therapies for rare neurological diseases. #RareDiseaseDay2026 #Biotech #Neuroscience

  • Quiver Bioscience reposted this

    We’re excited to announce a strategic research collaboration and licensing agreement with Angelini Pharma to discover and advance novel therapeutics for genetic epilepsies, including Developmental and Epileptic Encephalopathies (DEEs). This multi-year partnership combines Quiver’s GPS platform—human neuronal models, single-cell multimodal data, optical electrophysiology, and AI-driven analytics—with Angelini Pharma’s deep expertise in brain health and epilepsy drug development. Together, we aim to generate new functional and molecular insights to help unlock differentiated therapeutic targets for patients with urgent unmet need. 📰 Read the full press release here: https://lnkd.in/eSF8hJXh #Epilepsy #Neuroscience #DrugDiscovery #PrecisionMedicine #AIinBiotech #BrainHealth

    • No alternative text description for this image
  • We’re excited to announce a strategic research collaboration and licensing agreement with Angelini Pharma to discover and advance novel therapeutics for genetic epilepsies, including Developmental and Epileptic Encephalopathies (DEEs). This multi-year partnership combines Quiver’s GPS platform—human neuronal models, single-cell multimodal data, optical electrophysiology, and AI-driven analytics—with Angelini Pharma’s deep expertise in brain health and epilepsy drug development. Together, we aim to generate new functional and molecular insights to help unlock differentiated therapeutic targets for patients with urgent unmet need. 📰 Read the full press release here: https://lnkd.in/eSF8hJXh #Epilepsy #Neuroscience #DrugDiscovery #PrecisionMedicine #AIinBiotech #BrainHealth

    • No alternative text description for this image
  • Our CEO, Graham T. Dempsey, was recently interviewed on #TheGeneticsPodcast by Sano Genetics—a show dedicated to exploring cutting-edge science and breakthroughs in genetics research. In this episode, Graham discusses his journey into neuroscience and biotech, Quiver Bioscience's mission to transform CNS drug discovery, and how Quiver is advancing genetically validated therapeutics programs for pain and neurodevelopmental disorders. 🎧 Listen here: https://lnkd.in/edfS4C_6

    View organization page for Sano Genetics

    12,608 followers

    🎙️Episode 220 of #TheGeneticsPodcast is live! 🚀 This week, Patrick is joined by Graham Dempsey, CEO and co-founder of Quiver Bioscience. Tune in as they discuss: 🧠 How genetically validated sodium channel targets like Nav1.7 are reshaping approaches to chronic neuropathic pain 🧬 Quiver’s lead pain program and Dup15q neurodevelopmental program 🚀 The opportunities and tradeoffs of building a platform biotech at the intersection of RNA medicine and neuroscience Listen by following the link below 👇 or simply search “The Genetics Podcast” on your go-to podcast platform. 🎧 https://lnkd.in/eATyZm6n 📽️ https://lnkd.in/eCAanKfY Please consider rating and reviewing us on your chosen podcast listening platform! #Genetics #PrecisionMedicine #DrugDiscovery #PainDisorders #Neurodevelopment

    • No alternative text description for this image

Similar pages

Browse jobs

Funding